When you look at the potential of this stock, what's a fair value for a company that potentially could have a vaccine that had benefits for nearly every form of solid cancer, and perhaps even other diseases. That's the ultimate potential. In the interim, it may just be approved for GBM, initially in only the UK, but gradually other nations will fill in.
I believe initially we should be worth a couple billion, or more, depending on how the news of approval is handled. If the news is big in major media and stresses a new paradigm in cancer treatment, we may go much higher than a couple billion as demand for the stock could be huge. If not, $2 billion or more is warranted just looking at anticipated sales in the UK over the next few years. A $2 billion market cap ought to pencil out somewhere around $1.50. I don't know about others, for me that's better than a four banger, not a bad place to be.
Thing is, where is it going with acceptance worldwide, it may take a few years longer, but where does worldwide acceptance for GBM alone take us? I believe double digit billion dollar earnings will be in the cards, if you have that kind of growth the P/E of 30 should be justified. $10 billion in earnings would justify a $300 billion market cap, if shares outstanding grow to 3 billion, that's a $100 a share price. What happens if other cancers are included? If we're not bought out, this could be a trillion-dollar market cap company, it will take time, but I believe that's the possibility.
Gary
Bullish
Market Data 
Markets 
